Curie.Bio
Signal active
Investment Firm
Overview
Curie.Bio is a founder-focused seed-stage venture capital firm.
Highlights
Founded
2022
Industry
Biotechnology
Employees
11-50
Investment
9
Lead Investment
5
Exits
2
Stages
Seed, Early Stage Venture
Investor Type
Accelerator, Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
Curie.Bio, established in 2022 and headquartered in United States, North America., specializes in Seed, Early Stage Venture investments across Biotechnology, Health Care, Fitness, Wellness, Alternative Medicine, Venture Capital, Finance, Impact Investing, Medical, Health Diagnostics. The organization boasts a portfolio of 9 investments, with an average round size of $66.0M and 2 successful exits. Their recent investments include Tesseract Medical Research, Chengwei Capital, Thrive Earlier Detection, ROME Therapeutics, Google Ventures. The highest investment round they participated in was $45.2B. Among their most notable exits are Tesseract Medical Research and Chengwei Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Curie.Bio has made 9 investments. Their most recent investment was on Jun 11, 2024, when Tesseract Medical Research raised $20.0M.
Curie.Bio has made 4 diversity investments. Their most recent diversity investment was on Sep 12, 2023, when ROME Therapeutics raised $72.0M.
investments
9
Diversity investments
4
Lead investments
5
Number of exits
2
Investments
9
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jan 01, 2023 | Thrive Earlier Detection | Biotechnology | null |
| Sep 12, 2023 | ROME Therapeutics | Biotechnology | 72.0M |
| Jun 11, 2024 | Tesseract Medical Research | Biotechnology | 20.0M |
| Jul 04, 2024 | - | - | null |
Exits
2
Funding Timeline
Funding rounds
9
Investors
2
Funds
2
Funding Rounds
9
Curie.Bio has raised 9 rounds. Their latest funding was raised on Jul 04, 2024 from a Seed Round - Alkira Bio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jan 01, 2023 | Venture Round - Thrive Earlier Detection | - | 0 | - |
| Sep 12, 2023 | Series B - ROME Therapeutics | - | 72.0M | - |
| Jun 11, 2024 | Seed Round - Tesseract Medical Research | - | 20.0M | - |
| Jul 04, 2024 | Seed Round - Alkira Bio | - | 0 | - |
Investors
2
Curie.Bio is funded by 2 investor(s). Qiming Venture Partners and Wormhole Capital Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Wormhole Capital | No | Seed Round - Curie.Bio | 0 |
Qiming Venture Partners | Yes | Series B - Curie.Bio | 0 |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.